Lipid Profiles and Lipid-Lowering Therapy at the Time of Acute Myocardial Infarction Authors: Mohammed Essa, Qifan Wu, Yuan Lu, Nihar R Desai, Erica S Spatz, Abdel R Dajani, Michael Mankbadi, Bradley Kay, Kamil F Faridi Published: 2026 ABSTRACT AbstractBackgroundLow-density lipoprotein cholesterol (LDL-C) lowering with lipid-lowering therapy (LLT) is foundational for atherosclerotic cardiovascular disease (ASCVD) prevention.ObjectivesThe purpose of this study was to evaluate LDL-C levels and LLT at the time of acute myocardial infarction (AMI).MethodsWe retrospectively assessed LDL-C levels and LLT use at presentation and discharge among patients hospitalized with AMI from March 2018 to August 2022.ResultsAmong AMI patients with no prior ASCVD diagnosis (n = 1,159), 94.7% had LDL-C ≥55 mg/dL, 86.7% had LDL-C ≥70 mg/dL, and 33.6% were on outpatient statin therapy prior to admission. Among those not taking LLT and aged 18 to 79 years with available risk data, 89.0% met statin eligibility in the 2026 U.S. dyslpidemia guideline. Among AMI patients with prior ASCVD (n = 689), 81.0% had LDL-C ≥55 mg/dL, 64.7% had LDL-C ≥70 mg/dL, 73.7% were previously on statins, and 3.9% were on combination LLT. Although 94.0% of all AMI patients were discharged on statins (81.8% with high intensity), only 5.0% were discharged with combination LLT. Among patients with prior ASCVD and LDL-C ≥55 mg/dL, 24.9% had an increase in statin intensity, 7.2% received combination LLT, and 47.0% received no LLT intensification at discharge.ConclusionsIn a contemporary AMI cohort, ∼2 in 3 patients presenting with a new ASCVD diagnosis were not previously on a statin, and nearly all had LDL-C ≥55 mg/dL. Among AMI patients with known ASCVD, ∼1 in 4 were not on a statin, and ∼4 in 5 had LDL ≥55 mg/dL. Combination LLT remained low at presentation and discharge despite suboptimal LDL-C, underscoring actionable gaps in ASCVD management.Key words: acute myocardial infarction, ASCVD risk, LDL cholesterol, lipid goal, lipid-lowering therapy, primary prevention, secondary prevention Background Elevated low-density lipoprotein cholesterol (LDL-C) is a causal driver of atherosclerotic cardiovascular disease (ASCVD),1 and lowering LDL-C with statins reduces major adverse cardiovascular events in primary and secondary prevention populations.2 Randomized controlled trials of patients with ASCVD have consistently demonstrated that greater LDL-C reductions achieved with combination lipid-lowering therapy (LLT) reduce the risk of cardiovascular events.3, 4, 5 Accordingly, the 2019 European Society of Cardiology and the 2026 American College of Cardiology and American Heart Association (ACC/AHA) guidelines have emphasized aggressive LDL-C lowering to a target of <55 mg/dL in the vast majority of patients with existing ASCVD, including those with prior acute myocardial infarction (AMI).6, 7, 8 Despite the existing evidence and recommendations, LDL-C control and utilization of LLT for primary and secondary prevention in outpatient clinical care remain poor.9, 10, 11 Furthermore, evidence from randomized clinical trials now indicates that early LLT intensification after AMI rapidly lowers LDL-C and favorably modifies coronary plaque, supporting efforts to utilize combination LLT during the index hospitalization.12,13 However, most real-world studies describe LLT patterns in stable outpatient cohorts rather than at the index AMI event; these gaps may reflect missed opportunities in both primary prevention prior to the first ASCVD event and in intensifying therapy in patients with established ASCVD. Therefore, in this study, we evaluated lipid profiles, LDL-C goal attainment, and LLT prescription patterns at presentation and discharge among patients hospitalized with AMI at a large academic center. Methods We conducted a retrospective cohort analysis using data from the ACC National Cardiovascular Data Registry (NCDR) CathPCI Registry at Yale New Haven Hospital. The NCDR CathPCI Registry captures comprehensive clinical data for cardiac catheterization and percutaneous coronary intervention (PCI) procedures. All data are collected by trained abstractors and include patient demographics, comorbidities, laboratory values, procedural details, and medications; all variables are specified using standardized definitions provided by the NCDR.14 We included all adults in the Yale NCDR CathPCI Registry hospitalized with a diagnosis of ST-elevation myocardial infarction (STEMI) or type 1 non-ST-segment elevation myocardial infarction (NSTEMI) between March 2018 and August 2022. Given our focus on type 1 AMI and the use of high-sensitivity troponin assays at our institution, we excluded patients with type 2 NSTEMI and those without troponin elevation. Data on serum lipids were extracted from the electronic health record; we used values at the time of AMI hospitalization, if available, or otherwise used the most recent values available in the 6 months prior to admission. All LDL-C values were calculated using the Martin-Hopkins equation.15 Patient data were additionally supplemented with manual chart review to determine additional clinical characteristics, including prehospitalization outpatient blood pressure, medication prescriptions, and dosing at the time of admission and at discharge. In the study cohort, we assessed lipid profiles and outpatient LLT prescriptions (statins, ezetimibe, and PCSK9 inhibitors [PCSK9i]) immediately preceding the AMI presentation. Among patients surviving the AMI hospitalization, we also assessed LLT prescriptions at the time of discharge. We defined combination LLT as ≥2 agents, and LLT intensification at discharge was defined as an increase in intensity of statin dosing and/or the addition of a new LLT compared with outpatient therapy prior to admission. Analyses were performed in the total cohort and in subgroups based on ASCVD history (previous AMI or coronary intervention, cerebrovascular disease, or peripheral artery disease) prior to the index admission. In a prespecified subgroup of AMI patients aged 18 to 79 years without prior ASCVD and not previously on LLT, we evaluated prehospitalization guideline-recommended indications for statins using the 2018 AHA/ACC and 2026 ACC/AHA blood cholesterol guidelines.7,16 For patients with sufficient clinical data available, indicated statin use under the 2018 guideline was evaluated using LDL-C, diabetes status, and predicted 10-year ASCVD risk using the pooled cohort equations, and under the 2026 guideline using LDL-C, diabetes, chronic kidney disease status, and predicted 10- and 30-year ASCVD risk using the PREVENT equations. Clinical characteristics, lipid values, and LLT use were reported using means (SD), medians (interquartile range), and proportions as appropriate. For key proportions reported in the results, 95% confidence intervals were calculated using the Wilson score method. Univariable comparisons of continuous and categorical variables between groups were conducted using the Wilcoxon Rank-Sum and Chi-square tests, respectively. We assessed the association between patient characteristics and LDL-C goal <55 mg/dL attainment using multivariable logistic regression with adjustment for prior ASCVD status, prior statin use, age (per 10-year increase), sex, race/ethnicity (non-Hispanic Black, non-Hispanic Asian, Hispanic, other/unknown vs non-Hispanic White), hypertension, diabetes, and active tobacco use. Temporal trends in LDL-C goal attainment and discharge combination therapy were also assessed using logistic regression, with calendar year modeled as a continuous predictor. A P value <0.05 was considered statistically significant. This study was approved by the Yale Institutional Review Board, and requirements for informed consent were waived given the retrospective nature of the analysis. Results Study population The study cohort included 1,848 patients hospitalized with AMI, of whom 1,159 (62.7%) had no prior history of clinical ASCVD, and 689 (37.3%) had a prior diagnosis of ASCVD. Patients without prior ASCVD were younger (mean [SD] age: 63 [13] vs 70 [12] years) and had a lower burden of comorbidities, including hypertension (62.5% vs 86.8%), dyslipidemia (72.6% vs 94.3%), and diabetes (22.1% vs 43.1%). STEMI presentations were more common among patients without prior ASCVD than among those with prior ASCVD (38.7% vs 24.2%) (Table 1). Table 1Baseline Characteristics of Patients Admitted With Acute Myocardial InfarctionOverall (N = 1,848)No Prior ASCVD (n = 1,159)Prior ASCVD (n = 689)Demographics Age, y, mean (SD)66 (13)63 (13)70 (12) Female, n (%)535 (29)325 (28)210 (30)Race/ethnicity, n (%) White1,447 (78.3)907 (78.3)540 (78.4) Non-Hispanic Asian44 (2.4)30 (2.6)14 (2.0) Non-Hispanic Black172 (9.3)101 (8.7)71 (10.0) Hispanic37 (2.0)22 (1.9)15 (2.2) Other/Unknown148 (8.0)99 (8.5)49 (7.1)Clinical characteristics, n (%) Hypertension1,322 (71.5)724 (62.5)598 (86.8) Dyslipidemiaa1,492 (80.7)842 (72.6)650 (94.3) Diabetes history553 (29.9)256 (22.1)297 (43.1) Active tobacco use451 (24.4)312 (26.9)139 (20.2) Dialysis32 (1.7)15 (1.3)17 (2.5)Number of traditional risk factorsb, n (%) 0115 (6.2)106 (9.1)9 (1.3) 1384 (20.8)320 (27.6)64 (9.3) 2702 (38.0)425 (36.7)277 (40.2) 3558 (30.2)268 (23.1)290 (42.1) 489 (4.8)40 (3.5)49 (7.1)ASCVD history prior to admission, n (%) Prior MI414 (22.4)-414 (60.1) Peripheral vascular disease147 (8.0)-147 (21.3) Cerebrovascular disease200 (10.8)-200 (29.0) Prior CABG110 (6.0)-110 (16.0) Prior PCI334 (18.1)-334 (48.5)AMI presentation, n (%) NSTEMI1,232 (66.7)710 (61.3)522 (75.8) STEMI616 (33.3)449 (38.7)167 (24.2)Lipid-lowering therapy prior to admission, n (%) Any statin897 (48.5)389 (33.6)508 (73.7) High-intensity statin443 (24.0)132 (11.4)311 (45.1) Moderate-intensity statin248 (13.4)125 (10.8)123 (17.9) Low-intensity statin204 (11.0)129 (11.1)73 (10.6) Ezetimibe55 (3.0)17 (1.5)38 (5.5) PCSK9i9 (0.5)1 (<0.1)8 (1.2) Combination therapy38 (2.1)11 (0.9)27 (3.9) No LLT930 (50.3)763 (65.8)167 (24.2)Lipid-lowering therapy at discharge, n (%) Any statin1,737 (94.0)1,104 (95.3)633 (91.9) High-intensity statin1,511 (81.8)986 (85.1)525 (76.2) Moderate intensity131 (7.1)58 (5.0)73 (10.6) Low intensity14 (0.8)5 (0.4)9 (1.3) Ezetimibe111 (6.0)54 (4.7)57 (8.3) PCSK9i13 (0.7)3 (0.3)10 (1.5) Combination therapy92 (5.0)43 (3.7)49 (7.1) No LLT84 (4.5)42 (3.6)42 (6.1) LLT intensification1,247 (67.5)933 (80.5)314 (45.6)Lipid values, mg/dL, median (25th – 75th percentile)c Total cholesterol171 [138-206]182 [152-212]150 [124-189] HDL-C43 [35-52]44 [36-53]42 [35-51] Triglycerides116 [81-174]116 [82-172]116 [80-175] LDL-C102 [74-131]111 [84.0-137]83 [61-115] Non-HDL-C124 [94-158]134 [105.0-164]106 [81-144]LDL-C categories, mg/dL, n (%) <55192 (10.4)61 (5.3)131 (19.0) 55-69205 (11.1)93 (8.0)112 (16.3) 70-99503 (27.2)292 (25.2)211 (30.6) 100-129477 (25.8)364 (31.4)113 (16.4) 130-159285 (15.4)217 (18.7)68 (9.9) 160-189128 (6.9)92 (7.9)36 (5.2) ≥19058 (3.1)40 (3.5)18 (2.6)Non-HDL-C category, mg/dL, n (%) <100554 (30.0)247 (21.3)307 (44.6) 100–129437 (23.6)271 (23.4)166 (24.1) 130–159406 (22.0)317 (27.4)89 (12.9) 160–189236 (12.8)173 (14.9)63 (9.1) 190–219135 (7.3)95 (8.2)40 (5.8) ≥22080 (4.3)56 (4.8)24 (3.5)AMI = acute myocardial infarction; ASCVD = atherosclerotic cardiovascular disease; CABG = coronary artery bypass graft; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; LLT = lipid-lowering therapy; MI = myocardial infarction; NSTEMI = non–ST-elevation myocardial infarction; PCI = percutaneous coronary intervention.aDyslipidemia was defined as any of the following: a chart diagnosis, prior use of lipid-lowering therapy (statin, ezetimibe, and/or PCSK9i), LDL-C >130 mg/dL, or non-HDL-C >160 mg/dL.bTraditional risk factors include hypertension, dyslipidemia, diabetes, and active tobacco use.cLipid values reflect measurements obtained at the index AMI presentation, or if not available, the most recent values within 6 months prior to admission. Baseline Characteristics of Patients Admitted With Acute Myocardial Infarction AMI = acute myocardial infarction; ASCVD = atherosclerotic cardiovascular disease; CABG = coronary artery bypass graft; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; LLT = lipid-lowering therapy; MI = myocardial infarction; NSTEMI = non–ST-elevation myocardial infarction; PCI = percutaneous coronary intervention. Dyslipidemia was defined as any of the following: a chart diagnosis, prior use of lipid-lowering therapy (statin, ezetimibe, and/or PCSK9i), LDL-C >130 mg/dL, or non-HDL-C >160 mg/dL. Traditional risk factors include hypertension, dyslipidemia, diabetes, and active tobacco use. Lipid values reflect measurements obtained at the index AMI presentation, or if not available, the most recent values within 6 months prior to admission. LLT and lipid profiles at presentation In the total AMI cohort, 897/1,848 (48.5% [95% CI: 46.3%-50.8%]) were on outpatient statins prior to AMI hospitalization, including 389/1,159 (33.6% [95% CI: 30.9%-36.3%]) without prior ASCVD and 508/689 (73.7% [95% CI: 70.0%-76.9%]) with prior ASCVD. Among statin users, high-intensity statin use was lower among patients without prior ASCVD (132/389, 33.9% [95% CI: 29.4-38.8]) than among those with prior ASCVD (311/508, 61.2% [95% CI: 56.9%-65.4%]; P < 0.01). The use of nonstatin LLT was rare among patients without and with prior ASCVD (1.5% and 5.5% for ezetimibe, and <0.1% and 1.2% for PCSK9i, respectively) (Table 1). Among patients without prior ASCVD, those presenting with STEMI were less frequently receiving outpatient statin therapy before admission than those with NSTEMI; characteristics of patients with STEMI and NSTEMI are shown in Supplemental Table 1. Median (25th-75th percentile) LDL-C was 111 (84-137) mg/dL among patients without prior ASCVD and 83 (61-115) mg/dL among those with prior ASCVD. Among all patients, 1,656/1,848 (89.6%; 95% CI: 88.1%-90.9%) had a serum LDL-C ≥55 mg/dL and met criteria for LLT intensification based on current secondary prevention guidelines, including 1,098/1,159 (94.7%; 95% CI: 93.3%-95.9%) of patients without prior ASCVD and 558/689 (81.0%; 95% CI: 77.9-83.7) of patients with prior ASCVD. In the total cohort, 1,451/1,848 (78.5%; 95% CI: 76.6%-80.3%) of patients also had serum LDL-C ≥70 mg/dL, including 1,005/1,159 (86.7%; 95% CI: 84.6%-88.5%) of patients without prior ASCVD and 446/689 (64.7%; 95% CI: 61.1%-68.2%) with ASCVD. Regardless of the ASCVD history, patients taking statins were more likely to achieve LDL-C <55 mg/dL and <70 mg/dL thresholds. Even so, among statin-users, only 11.1% of patients without prior ASCVD and 22.8% with prior ASCVD had LDL-C <55 mg/dL (Figure 1). In multivariable adjusted analyses, prior ASCVD (OR: 1.99; 95% CI: 1.40-2.85; P < 0.01) and prior statin use (OR: 3.61, 95% CI: 2.39-5.58; P < 0.01) were associated with higher odds of LDL-C <55 mg/dL. Older age (per 10-year increase: OR: 1.54; 95% CI: 1.32-1.79; P < 0.01) and diabetes (OR: 1.94; 95% CI: 1.39-2.71; P < 0.01) were also associated with higher odds of having LDL-C <55 mg/dL. Sex, race/ethnicity, hypertension, and active tobacco use were not significantly associated with having LDL-C <55 mg/dL (Supplemental Table 2). LDL-C Levels in Patients Hospitalized With Acute Myocardial Infarction The figure illustrates the distribution of LDL-C values and the proportion of patients achieving LDL-C <55 mg/dL and <70 mg/dL among patients hospitalized with acute myocardial infarction, stratified by history of clinical ASCVD and prior home statin use. LDL-C values reflect measurements obtained at the index acute myocardial infarction presentation, or if not available, the most recent values within 6 months prior to admission. Within each ASCVD stratum, statin users had lower LDL-C values and a higher frequency of LDL-C <55 mg/dL or <70 mg/dL (P < 0.01 for all comparisons). ASCVD = atherosclerotic cardiovascular disease; LDL-C = low-density lipoprotein cholesterol. Over the study period from 2018 to 2022, we did not find any significant changes in the proportion of patients achieving low LDL-C goals. Among patients without prior ASCVD, attainment of LDL-C <55 mg/dL was 5.6% in 2018 and 4.7% in 2022 (P for trend = 0.88), and LDL-C <70 mg/dL was 14.3% in 2018 and 14.1% in 2022 (P for trend = 0.53). Among patients with prior ASCVD, the proportion with LDL-C <55 mg/dL was 19.1% in 2018 and 22.2% in 2022 (P for trend = 0.41), and the proportion with LDL-C <70 mg/dL was 31.6% in 2018 and 32.3% in 2022 (P for trend = 0.99) (Supplemental Figure 1). Among patients aged 18 to 79 years without prior ASCVD who were not previously receiving statin therapy, 394/574 (68.6%) met guideline indications for LLT under the 2018 guidelines, including 358/574 (62.4%) with pooled cohort equation 10-year ASCVD risk ≥7.5%. Under the 2026 guidelines, 511/574 (89.0%) met indications for LLT, including 326/574 (56.8%) with PREVENT 10-year ASCVD risk ≥3%, 151/574 (26.3%) with PREVENT 30-year risk ≥10%, 86/574 (14.9%) with diabetes, and 47/574 (8.2%) with chronic kidney disease. Detailed reasons for eligibility and predicted ASCVD risk distributions are shown in Supplemental Table 3. When stratified by LDL-C <100 vs ≥100 mg/dL, patients with LDL-C ≥100 mg/dL were more likely to meet guideline indications for LLT under both guidelines, though 68.4% of patients with LDL-C <100 mg/dL still met 2018 guideline indications, and 74.3% met 2026 guideline indications for statins (Supplemental Table 4). Discharge prescribing and intensification LLT prescribing changed substantially from admission to discharge, with overall LLT intensification occurring in 1,247/1,848 (67.5%; 95% CI: 65.3%-69.6%), driven primarily by new statin initiation (observed in 878/1,848 [47.5%, 95% CI: 45.2%-49.8%]) or an increase in statin intensity (observed in 377/1,848 [20.4%, 95% CI: 18.6%-22.3%]) (Table 1, Figure 2). At discharge, statins were prescribed to 1,104/1,159 (95.3%; 95% CI: 93.9%-96.3%) of patients without prior ASCVD and 633/689 (91.9%; 95% CI: 89.6%-93.7%) of patients with prior ASCVD; high-intensity statins were prescribed in 986/1,159 (85.1%; 95% CI: 82.9%-87.0%) and 525/689 (76.2%; 95% CI: 72.9%-79.2%), respectively. However, nonstatin and combination therapy remained uncommon at discharge (ezetimibe 6.0%, PCSK9i 0.7%; combination therapy 5.0%). LLT intensification from admission to discharge was more frequent among those without prior ASCVD than among those with prior ASCVD (80.5% vs 45.6%) (Table 1, Figure 2). Patients presenting with STEMI had higher rates of LLT intensification and new statin initiation than patients with NSTEMI (Supplemental Table 1). Among patients with prior ASCVD and LDL-C ≥55 mg/dL, 139/558 (24.9%) had an increase in statin intensity, 40/558 (7.2%) received combination LLT with ezetimibe or a PCSK9i, and 262/558 (47.0%) received no LLT intensification at discharge. Among ASCVD patients with LDL-C ≥55 mg/dL already on a statin, 138/392 (35.2%) had an increase in statin intensity, 33/392 (8.4%) received combination LLT, and 239/392 (61.0%) had no LLT intensification at discharge. Discharge combination LLT remained uncommon from 2018 through 2022 but modestly increased among patients without prior ASCVD (2.2% in 2018 and 7.0% in 2022; P for trend = 0.03). Discharge combination therapy did not change over time for patients with prior ASCVD (6.6% in 2018 and 7.1% in 2022; P for trend = 0.95) (Supplemental Table 5, Supplemental Figure 1). Overall findings were similar before and during the COVID-19 pandemic (Supplemental Table 6). Transitions in Lipid-lowering Therapy From Admission to Discharge in Patients Hospitalized With Acute Myocardial Infarction The figure shows changes in lipid-lowering therapy from admission (prior outpatient therapy) to hospital discharge among patients without prior clinical ASCVD (left panel) and with prior ASCVD (right panel). Categories include no statin, low-/moderate-intensity statin, high-intensity statin, and combination therapy (statin plus ≥1 nonstatin agent). The width of each flow curve represents the proportion of patients transitioning between categories, and bars represent the distribution of LLT categories at admission and at discharge. ASCVD = atherosclerotic cardiovascular disease; LLT = lipid-lowering therapy. Discussion In this real-world study of patients hospitalized with AMI, we found major gaps in both primary and secondary preventive care. Approximately 2 in 3 patients without prior clinical ASCVD and one in 4 patients with prior ASCVD were not taking any LLT. Among all AMI patients, 9 in 10 had LDL-C ≥55 mg/dL, and 4 in 5 had LDL-C ≥70 mg/dL on presentation. Although prescription of high-intensity statins at discharge was high, only 5% were prescribed combination LLT with either ezetimibe or PCSK9i. These findings highlight missed opportunities for primary and secondary prevention before AMI and show that, despite clear benefits and guideline-based indications, combination LLT initiation during AMI hospitalization remains extremely rare in real-world practice (Central Illustration). Lipid-Lowering Therapy Gaps at the Time of Acute Myocardial Infarction Among 1,848 adults hospitalized with AMI in the Yale NCDR CathPCI Registry from March 2018 to August 2022, lipid profiles and LLT use were assessed at presentation and discharge, stratified by prior ASCVD history. LDL-C values reflect measurements obtained at the index AMI presentation, or if not available, the most recent values within 6 months prior to admission. AMI = acute myocardial infarction; ASCVD = atherosclerotic cardiovascular disease; LDL-C = low-density lipoprotein cholesterol; LLT = lipid-lowering therapy; NCDR = National Cardiovascular Data Registry. In our analysis, AMI patients without prior clinical ASCVD were less frequently treated with LLT before presentation and had higher LDL-C, highlighting missed opportunities for risk identification and earlier initiation of therapy for primary prevention. Importantly, this gap indicates suboptimal implementation of ASCVD-prevention recommendations, since 69% of patients not taking statins and without a prior diagnosis of ASCVD already met indications for LLT under the 2018AHA/ACC guideline.16 Notably, unlike any prior studies, we also found that 89% of these patients would have met statin indications under the 2026 ACC/AHA guideline, suggesting only a small proportion of all AMI patients would not have previously met criteria for LLT based on current evidence-based recommendations.7 The 2026 guideline newly incorporates PREVENT 10- and 30-year ASCVD risk estimates and other variables, including renal function; with expanded eligibility criteria, an additional 20% of untreated primary-prevention patients were recommended for LLT prior to their first AMI compared to the 2018 guidelines. These findings suggest that implementation gaps in primary prevention may now be even larger than previously recognized, particularly upstream of the initial AMI event. Patients with prior ASCVD in our study had higher baseline statin use and lower LDL-C levels, yet one in 4 were still not taking a statin prior to AMI, and utilization of nonstatin therapies was rare. In addition, this patient group also had low rates of achieving LDL-C <55 mg/dL (19%) or <70 mg/dL (34%). Patients on home statins achieved lower LDL-C levels, with 23% and 43% reaching LDL-C <55 mg/dL and <70 mg/dL, respectively, compared with 8% and 13% among those not on home statins, underscoring the importance of continued statin use to lower LDL-C levels in this high-risk group. Nevertheless, achievement of guideline-recommended LDL-C thresholds remained low even among patients on home statins. With only 4% of ASCVD patients previously receiving combination LLT, these findings further highlight significant treatment gaps among patients already known to be at high risk prior to AMI admission. Our findings are consistent and complementary with other real-world data demonstrating persistently low use of statins in outpatient primary and secondary prevention populations, and low adoption of nonstatin therapies and achievement of LDL-C goals in patients with established ASCVD.9, 10, 11 Unlike prior studies, we further show that underutilization of LLT and suboptimal LDL-C control are widely prevalent among contemporary patients presenting with a new AMI, demonstrating upstream failures in preventive care despite guideline recommendations. We additionally found that two-thirds of patients had intensification of LLT from admission to discharge, driven almost completely by prescriptions for high-intensity statins at discharge in patients not previously receiving them. Although this reflects successful implementation of guideline recommendations for patients presenting with AMI, combination therapy remained rare with no significant change over time. Since the vast majority of AMI patients had LDL-C ≥55 mg/dL and ≥70 mg/dL at presentation, our study suggests that AMI hospitalization remains a missed opportunity for more aggressive secondary prevention. This is particularly notable given that randomized trials have demonstrated that early initiation of combination LLT after AMI rapidly lowers LDL-C, favorably modifies coronary plaque, and reduces recurrent cardiovascular events.3, 4, 5,12,13,17 Low utilization of combination LLT could reflect perceived implementation barriers to initiating PCSK9i in the in-hospital setting, including prior authorization requirements, out-of-pocket costs, and subcutaneous administration. However, ezetimibe is generic, safe, and easily administered as a second agent on top of statins,18 yet it also remained infrequently used in our cohort. In addition, while high-intensity statins remain a class I recommendation and are foundational for post-AMI lipid management, combination LLT should be viewed as a necessary escalation strategy when maximally tolerated statin therapy is insufficient to achieve recommended LDL-C thresholds. This is particularly relevant because doubling the statin dose results in only a ∼6% decrease in LDL-C, on average.19 Recent clinical trial data also indicate that moderate-intensity statin combined with ezetimibe lowers LDL-C levels and results in fewer adverse effects and drug discontinuation than high-intensity statin alone.20,21 Future work should investigate practical strategies to intensify LLT at the time of AMI hospitalization. These could include standardized treatment pathways, automated Electronic Health Record-based identification with treatment recommendations, and streamlined processes for PCSK9i prescriptions. Study Limitations This study has important limitations. All data are from a single academic center and are limited to AMI patients captured in the NCDR CathPCI Registry, which may limit generalizability to other settings. For example, because Yale-New Haven Hospital is a large tertiary medical center with an expanded health network, the treatment gaps observed in our study may underestimate those in hospitals or health systems with fewer resources. Data on the attending physician or clinical service responsible for discharge medications were not available in the NCDR CathPCI Registry and therefore could not be assessed. However, given that our entire cohort had a type 1 AMI and underwent cardiac catheterization, cardiologists were likely directly involved in the care of nearly all patients. All lipid values we analyzed were obtained at presentation or within 6 months prior, and LLT use was based on prescribed therapies rather than confirmed adherence. In addition, prior coronary artery calcium from imaging was not available in our dataset, which may have impacted LLT use or identified additional opportunities for earlier ASCVD risk detection. Certain other variables, such as body mass index and lipoprotein(a), were also not available in NCDR CathPCI Registry data and could not be evaluated in our analyses. We also did not assess postdischarge medication use or subsequent lipid values. Lastly, our results are limited to patients with biomarker-confirmed type 1 AMI, and findings could differ for other populations such as those with unstable angina or high-risk chest pain. Conclusions In this analysis within a large health system, 2 in 3 AMI patients presenting with a new ASCVD diagnosis were not previously on a statin, and nearly all had LDL-C ≥55 mg/dL. Among patients with previously diagnosed ASCVD presenting with AMI, 1 in 4 were not previously on a statin, and 4 in 5 had LDL ≥55 mg/dL. Although the vast majority of AMI patients received high-intensity statins at discharge, combination LLT at presentation and discharge remained infrequent despite suboptimal LDL-C in most patients, underscoring significant and actionable prevention gaps in ASCVD management. These data emphasize the need for more effective implementation strategies to achieve LDL-C goals and reduce future risk among patients hospitalized with AMI. COMPETENCY IN SYSTEM-BASED PRACTICE: Most patients presenting with AMI had suboptimal LDL-C levels, reflecting missed opportunities for primary and secondary prevention. TRANSLATIONAL OUTLOOK: Greater implementation of guideline-directed lipid-lowering therapy, including combination therapy when appropriate, is needed across outpatient and inpatient care settings to improve LDL-C control and reduce cardiovascular risk. Funding support and author disclosures This research was funded in part by a grant from the NIH/NHLBI under award K23HL161424. Dr Lu receives support from the Sentara Research Foundation, the National Heart, Lung, and Blood Institute of the National Institutes of Health under awards R01HL69954 and R01HL169171, and the Patient-Centered Outcomes Research Institute under award HM-2022C2-28354, outside the submitted work. Dr Desai works under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures used for public reporting and pay-for-performance programs and has received research grants and consulting fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, SCPharmaceuticals, and Vifor, outside the submitted work. Dr Spatz reports receiving grants from the US Food and Drug Administration to support projects within the Yale University–Mayo Clinic Center of Excellence in Regulatory Science and Innovation and from the Patient-Centered Outcomes Research Institute, the National Heart, Lung, and Blood Institute, the Centers for Disease Control and Prevention, the National Institute of Biomedical Imaging and Bioengineering, and the National Institute on Minority Health and Health Disparities, outside the submitted work. Dr Faridi receives research funding from the NIH/NHLBI under award K23HL161424. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For supplemental tables and figures, please see the online version of this paper. Supplementary material Supplemental Material References Associated Data Supplementary Materials Supplemental Material